Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rectal Neoplasms × Temozolomide × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 140 Brain Neoplasms 64 Glioma 59 Central Nervous System Neoplasms 44 Gliosarcoma 43 Astrocytoma 35 Melanoma 28 Oligodendroglioma 27 Neuroblastoma 16 Neoplasm Metastasis 11 Medulloblastoma 10 Sarcoma, Ewing 9 Sarcoma 9 Neuroendocrine Tumors 9 Carcinoma, Non-Small-Cell Lung 9 Recurrence 8 Lung Neoplasms 8 Ependymoma 8 Neoplasms 7 Lymphoma 7 Diffuse Intrinsic Pontine Glioma 7 Breast Neoplasms 7 Rhabdomyosarcoma 6 Ovarian Neoplasms 6 Small Cell Lung Carcinoma 5 Colorectal Neoplasms 5 Carcinoma, Neuroendocrine 5 Adenoma, Islet Cell 5 Uveal Melanoma 4 Spinal Cord Neoplasms 4

Interventions

Oxaliplatin 132 Fluorouracil 124 Capecitabine 106 Leucovorin 98 Irinotecan 75 Radiotherapy 63 Bevacizumab 59 Cetuximab 41 Folfox protocol 25 Surgical Procedures, Operative 22 Drug Therapy 21 Radiation 18 Panitumumab 17 XELOX 16 Chemotherapy, Adjuvant 15 Neoadjuvant Therapy 14 Chemoradiotherapy 13 Radiotherapy, Intensity-Modulated 12 Floxuridine 10 regorafenib 8 Nivolumab 8 raltitrexed 7 aflibercept 7 IFL protocol 7 Celecoxib 7 trifluridine tipiracil drug combination 6 sintilimab 6 Trastuzumab 6 Melphalan 6 Magnetic Resonance Spectroscopy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05136326 2023-03-01

CATARTIC

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡